术前放化疗后 HIF-1α 和 GLUT-1 的表达与直肠癌患者的预后无关。
Pretreatment HIF-1α and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer.
机构信息
Department of Oncology, Vejle Hospital, Denmark.
出版信息
Anticancer Res. 2011 May;31(5):1559-65.
UNLABELLED
The aim of the present study was to investigate hypoxia-inducible factor 1α (HIF-1α) and glucose transporter-1 (GLUT-1) expressions as predictors of response and survival after chemoradiotherapy in pretreatment biopsy specimens from patients with rectal cancer.
MATERIALS AND METHODS
The immunohistological expressions of HIF-1α and GLUT-1 were investigated in pretreatment biopsies from 86 patients with rectal cancer receiving long course preoperative chemoradiotherapy. The immunohistological stainings were scored semi-quantitatively (percentage of stained cells and staining intensity), and an immunoreactive score was calculated. The response to the chemoradiotherapy was assessed by the Mandard Tumour Regression Grade system (TRG).
RESULTS
No association was found between HIF-1α or GLUT-1 and clinicopathological variables. HIF-1α and GLUT-1 expression had no predictive impact regarding response to chemoradiotherapy measured by TRG and was not associated with overall survival.
CONCLUSION
The present study did not suggest any predictive or prognostic value of pretreatment HIF-1α or GLUT-1 expression in patients with rectal cancer treated with preoperative chemoradiotherapy.
目的
本研究旨在探讨缺氧诱导因子 1α（HIF-1α）和葡萄糖转运蛋白-1（GLUT-1）的表达作为直肠癌患者放化疗前活检标本预测反应和生存的指标。
材料与方法
对 86 例接受长程术前放化疗的直肠癌患者的放化疗前活检标本进行 HIF-1α和 GLUT-1 的免疫组织化学表达研究。采用半定量（染色细胞百分比和染色强度）方法对免疫组化染色进行评分，并计算免疫反应评分。通过 Mandard 肿瘤消退分级系统（TRG）评估放化疗的反应。
结果
HIF-1α 或 GLUT-1 与临床病理变量之间无相关性。HIF-1α 和 GLUT-1 的表达与 TRG 测量的放化疗反应无预测作用，与总生存无关。
结论
本研究提示，术前放化疗治疗的直肠癌患者，放化疗前 HIF-1α 或 GLUT-1 的表达无预测或预后价值。
Zotero 插件